PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'GI Associates, Flowood, MS, USA. Electronic address: reed.hogan@gi.md.\', \'GI Associates, Flowood, MS, USA.\', \'Jackson Pulmonary Associates PA, Jackson, MS, USA.\', \'Medical Marketing Economics (MME) and University of Mississippi, Oxford, MS, USA.\', \'Trends in Pharma Development LLC, Pinson, AL, USA. Electronic address: tom@tomdooley.org.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1094-5539(20)30146-210.1016/j.pupt.2020.101942
?:hasPublicationType
?:journal
  • Pulmonary pharmacology & therapeutics
is ?:pmid of
?:pmid
?:pmid
  • 32871242
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32871242>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32871242>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all